

id	study	pa	year	size with data	size overall	site	method	endpoint	context	% with abnormal			
										p53	antibody	criterion	from exon
81	adell	p	1999	163	163	rectum	IHC	local control	local preop	41% Pab-1801	0.05	*****	
82	adell	p	1999	85	85	rectum	IHC	local control	local preop	45% Pab-1801	0.05	*****	
83	adell	p	1999	78	78	rectum	IHC	local control	local preop	37% Pab-1801	0.05	*****	
44	adrover	p	1999	30	30	colorectal	IHC	survival	post surg. adj.	33% DO-1	0.99	*****	
30	ahnen	p	1998	194	194	colon	IHC	survival	post surg. adj.	64% DO-7	0.05	*****	
26	allegra	p	2003	700	700	colon	IHC	survival	post surg. adj.	54% DO-7	0.1	*****	
20	allegra	p	2002	463	463	colorectal	IHC	survival	post surg. adj.	60% DO-7	0.1	*****	
29	allegra	p	2003	700	700	colon	IHC	FFS	post surg. adj.	54% DO-7	0.1	*****	
84	aoki	p	2002	68	68	colorectal	mut	survival	post surg. adj.	59% *****	*****		5
41	auvinenen	p	1994	144	144	colon	IHC	survival	post surg. adj.	69% CM-1	0.2	*****	
64	backus	p	2001	29	29	colorectal	IHC	survival	advanced / mets.	21% DO-7	0.25	*****	
85	backus	p	2001	30	29	colorectal	IHC	response	advanced / mets.	21% DO-7	0.25	*****	
59	baretton	p	1996	95	95	colorectal	IHC	FFS	post surg. adj.	42% DO-1	0.2	*****	
53	bartik	p	1997	82	257	colorectal	IHC	survival	post surg. adj.	44% DO-1	0.05	*****	
86	bell	p	1993	100	100	colorectal	IHC	survival	post surg. adj.	46% Pab421	0.01	*****	
78	belluco	p	1996	48	50	colorectal	IHC	survival	advanced / mets.	72% Pab-1801	0.1	*****	
87	belluco	p	1996	50	50	colorectal	IHC	response	advanced / mets.	72% Pab-1801	0.1	*****	
88	benhattar	p	1996	17	17	colorectal	mut	survival	advanced / mets.	47% *****	*****		5
256	berglund	p	2002	120	136	colorectal	IHC	response	advanced / mets.	60% DO-7	0.05	*****	
89	bhatavdekar	p	1997	48	48	colorectal	IHC	survival	post surg. adj.	38% DO-7	0.05	*****	
90	bleeker	p	2001	55	55	colon	mut	survival	post surg. adj.	44% *****	*****		5
91	borreson-d	p	1998	222	222	colorectal	mut	survival	post surg. adj.	46% *****	*****		5
92	bosari	p	1995	126	126	colorectal	mut	survival	post surg. adj.	59% *****	*****		5
93	bosari	p	1994	206	206	colorectal	IHC	survival	post surg. adj.	46% Pab-1801	0.01	*****	
94	bouzouren	p	2000	122	122	colorectal	mut	survival	post surg. adj.	32% *****	*****		5
46	bouzouren	p	2000	112	122	colorectal	IHC	survival	post surg. adj.	47% DO-7	0.1	*****	
95	brett	p	1996	59	59	colorectal	IHC	response	advanced / mets.	49% DO-1	0.05	*****	
77	buglioni	p	2001	94	94	colorectal	IHC	survival	post surg. adj.	53% DO-7	0.01	*****	
96	buglioni	p	1999	141	171	colorectal	IHC	survival	post surg. adj.	72% DO-7	0.01	*****	
76	buglioni	p	2001	94	94	colorectal	IHC	FFS	post surg. adj.	53% DO-7	0.01	*****	
80	buglioni	p	1999	119	171	colorectal	IHC	FFS	post surg. adj.	72% DO-7	0.01	*****	
98	bukholm	p	2000	93	93	colon	IHC	survival	post surg. adj.	60% DO-1	0.1	*****	

id	study	pa	year	size with	size	site	method	endpoint	context	% with		criterion	from exon
				data	overall					p53	antibody		
	97 bukholm	p	2000	93	93	colon	IHC	metastases	post surg. adj.	60%	DO-1	0.1	*****
	60 caldes	p	1998	72	72	colorectal	mut	survival	post surg. adj.	26%	*****	*****	5
	43 caldes	p	1998	72	72	colorectal	IHC	survival	post surg. adj.	56%	DO-7	*****	*****
	99 cascinu	p	2000	41	41	colorectal	IHC	response	advanced / mets.	66%	53-12	0.2	*****
	48 cascinu	p	2002	79	79	rectum	IHC	FFS	post surg. adj.	46%	DO-7	0.1	*****
	100 chen	p	1997	70	70	colorectal	IHC	FFS	post surg. adj.	69%	Pab-1801	0.01	*****
	101 chen	p	1997	45	45	colorectal	IHC	FFS	post surg. adj.	69%	Pab-1801	0.01	*****
	102 chen	p	1997	25	25	colorectal	IHC	FFS	post surg. adj.	68%	Pab-1801	0.01	*****
	103 clarke	p	1999	134	134	colorectal	IHC	survival	post surg. adj.	58%	DO-7	0.01	*****
	257 costa	p	1997	104	104	colorectal	IHC	FFS	advanced / mets.	59%	Pab-1801	0.05	*****
	105 desai	p	1996	23	23	rectum	IHC	FFS	local preop	43%	Pab-1801	*****	*****
	104 desai	p	1996	20	23	rectum	IHC	response	local preop	43%	Pab-1801	*****	*****
	108 diez	p	1997	37	37	rectum	IHC	FFS	local preop	65%	CM-1	0.01	*****
	109 diez	p	1997	30	37	rectum	IHC	FFS	local preop	65%	CM-1	0.01	*****
	107 diez	p		130	130	rectum	IHC	FFS	post surg. adj.	58%	CM-1	0.1	*****
	65 diez	p		190	190	colorectal	IHC	FFS	post surg. adj.	53%	CM-1	0.1	*****
	69 diez	p	2000	174	174	colorectal	IHC	FFS	post surg. adj.	47%	CM-1	0.01	*****
	74 diez	p	1995	61	61	colorectal	IHC	FFS	post surg. adj.	44%	CM-1	0.01	*****
	106 diez	p		60	60	colon	IHC	FFS	post surg. adj.	42%	CM-1	0.1	*****
	110 dominguez	a	1994	73	73	colorectal	IHC	survival	post surg. adj.	49%	DO-7	0.99	*****
	112 edler	p	2000	109	109	rectum	IHC	survival	local preop	69%	DO-7	0.05	*****
	111 edler	p	2000	109	109	rectum	IHC	metastases	local preop	69%	DO-7	0.05	*****
	114 elsaleh	p	2000	48	48	rectum	mut	response	local preop	35%	*****	*****	5
	115 elsaleh	p	2000	48	48	rectum	other	response	local preop	46%	*****	*****	*****
	15 elsaleh	p	1999	122	122	rectum	mut	survival	post surg. adj.	39%	*****	*****	5
	113 elsaleh	p	2000	48	48	rectum	IHC	response	local preop	40%	DO-7	0.05	*****
	17 elsaleh	p	1999	118	122	rectum	IHC	survival	post surg. adj.	39%	DO-7	0.05	*****
	116 esposito	p	2001	38	38	rectum	IHC	response	local preop	45%	Pab-1801	0.1	*****
	66 etienne	p	2002	97	97	colorectal	mut	survival	advanced / mets.	57%	*****	*****	4
	117 fante	p	1996	150	150	colorectal	IHC	survival	post surg. adj.	47%	Pab-1801	0.01	*****
	242 finkelstein	p	1996	204	204	colorectal	mut	survival	post surg. adj.	67%	*****	*****	5
	118 flamini	p	1996	94	94	colorectal	IHC	FFS	post surg. adj.	48%	DO-7	0.01	*****

id	study	pa	year	size with	size	site	method	endpoint	context	% with			
				data	overall					p53	antibody	criterion	from exon
248	fraczadi	p	2003	20	20	rectum	other	survival	local preop		other	99	*****
120	fu	p	1998	46	46	rectum	IHC	survival	local preop	48%	DO-7	0.05	*****
119	fu	p	1998	49	49	rectum	IHC	response	local preop	49%	DO-7	0.05	*****
121	gallego	p	2000	126	126	rectum	IHC	survival	local preop	67%	DO-7	0.01	*****
122	gallego	p	2000	126	126	rectum	IHC	survival	post surg. adj.	67%	DO-7	0.01	*****
255	garrity	p	2004	365	1388	colon	IHC	FFS	post surg. adj.	76%	DO-7	0.99	*****
254	garrity	p	2004	365	1388	colon	IHC	survival	post surg. adj.	76%	DO-7	0.99	*****
123	gervaz	p	2001	122	122	colorectal	mut	survival	post surg. adj.	32%	*****	*****	5
47	gervaz	p	2001	154	122	colorectal	IHC	survival	post surg. adj.	47%	DO-7	0.1	*****
70	gervaz	p	2002	88	88	colorectal	IHC	survival	post surg. adj.	44%	DO-7	0.1	*****
129	giatromanc	p	1999	106	106	colorectal	IHC	survival	post surg. adj.	44%	DO-7	0.1	*****
126	giatromanc	p	2001	268	268	colorectal	IHC	FFS	post surg. adj.	46%	DO-7	0.05	*****
128	giatromanc	p	1999	108	106	colorectal	IHC	FFS	post surg. adj.	44%	DO-7	0.1	*****
127	giatromanc	p	2001	70	70	rectum	IHC	FFS	post surg. adj.	29%	DO-7	0.05	*****
124	giatromanc	p	2001	268	268	colorectal	IHC	local control	post surg. adj.	46%	DO-7	0.05	*****
125	giatromanc	p	2001	70	70	rectum	IHC	local control	post surg. adj.	29%	DO-7	0.05	*****
131	goh	p	1999	130	130	rectum	mut	survival	post surg. adj.	55%	*****	*****	4
132	goh	p	1999	198	198	colon	mut	survival	post surg. adj.	47%	*****	*****	4
130	goh	p	1999	328	328	colorectal	mut	metastases	post surg. adj.	51%	*****	*****	4
241	gonzalez-a	p	2004	77	96	colorectal	mut	FFS	post surg. adj.	39%	*****	*****	
134	grewal	p	1995	66	66	colorectal	IHC	survival	post surg. adj.	52%	Pab-1801	0.01	*****
133	grewal	p	1995	66	66	colorectal	IHC	local control	post surg. adj.	52%	Pab-1801	0.01	*****
16	gunther	p	2002	115	115	rectum	IHC	metastases	post surg. adj.	58%	DO-1	0.1	*****
135	hallak	p	1998	119	120	colorectal	IHC	metastases	post surg. adj.	55%	DO-1	0.99	*****
51	hamelin	p	1994	85	85	colorectal	mut	survival	post surg. adj.	52%	*****	*****	5
42	hardinghan	p	1998	100	100	colorectal	mut	survival	post surg. adj.	55%	*****	*****	5
71	haseba	p	2003	73	79	colorectal	mut	FFS	post surg. adj.	71%	*****	*****	5
136	hayashi	p	1995	61	61	colorectal	mut	survival	post surg. adj.	20%	*****	*****	5
137	heisterkam	p	1999	45	45	colorectal	IHC	FFS	advanced / mets.	53%	DO-7	0.1	*****
138	hirano	p	2000	71	71	colorectal	IHC	metastases	post surg. adj.	35%	CM-1	0.3	*****
140	hirvikoski	p	1999	98	98	rectum	mut	survival	post surg. adj.	39%	*****	*****	4
24	hirvikoski	p	1999	96	96	rectum	IHC	survival	post surg. adj.	54%	CM-1	0.2	*****

id	study	pa	year	size with data	size overall	site	method	endpoint	context	% with abnormal			
										p53	antibody	criterion	from exon
139	hirvikoski	p	1999	97	97	rectum	IHC	survival	post surg. adj.	71% DO-7	0.2	*****	
141	ichikawa	p	1996	15	15	rectum	mut	response	local preop	53% *****	*****		5
142	ilyas	p	1998	66	66	colorectal	IHC	FFS	post surg. adj.	56% DO-7	0.1	*****	
68	iniesta	p	1998	37	61	colorectal	mut	survival	post surg. adj.	30% *****	*****		5
143	jansson	p	2001	75	75	colorectal	mut	survival	post surg. adj.	55% *****	*****		5
144	jingwei	a	1998	40	40	colorectal	IHC	survival	post surg. adj.	50% DO-7	0.99	*****	
145	kahlenberg	p	2000	56	56	colorectal	mut	survival	post surg. adj.	50% *****	*****		5
22	kahlenberg	p	2000	56	56	colorectal	mut	FFS	post surg. adj.	50% *****	*****		5
149	kandolier	p	2002	64	64	rectum	mut	survival	local preop	45% *****	*****		2
148	kandolier	p	2002	64	64	rectum	mut	local control	local preop	45% *****	*****		2
147	kandolier	p	2002	64	64	rectum	mut	response	local preop	45% *****	*****		2
146	kandolier	p	2002	64	64	rectum	mut	metastases	local preop	45% *****	*****		2
151	kang	p	1997	163	163	colorectal	IHC	survival	post surg. adj.	42% DO-7	0.1	*****	
150	kang	p	1997	101	101	colorectal	IHC	FFS	post surg. adj.	40% DO-7	0.1	*****	
152	kapiteijn	p	2001	39	39	rectum	IHC	survival	post surg. adj.	64% DO-7	0.25	*****	
153	kapiteijn	p	2001	34	34	colon	IHC	survival	post surg. adj.	29% DO-7	0.25	*****	
154	khan	p	2001	27	27	colorectal	mut	response	advanced / mets.	78% *****	*****		4
155	kim	p	2001	23	23	rectum	IHC	response	local preop	70% DO-7	0.1	*****	
156	kim	p	1995	387	471	colorectal	IHC	survival	post surg. adj.	45% DO-7	0.01	*****	
10	klump	p	2003	125	125	colon	IHC	survival	post surg. adj.	46% DO-1	0.05	*****	
11	klump	p	2003	133	133	colon	IHC	survival	post surg. adj.	41% DO-1	0.05	*****	
12	klump	p	2003	113	113	colon	IHC	survival	post surg. adj.	39% DO-1	0.05	*****	
158	kotera	p	1997	58	58	rectum	IHC	survival	local preop	31% rsp53	0.01	*****	
157	kotera	p	1997	58	58	rectum	IHC	local control	local preop	31% rsp53	0.01	*****	
34	kressner	p	1999	186	186	colorectal	mut	survival	post surg. adj.	53% *****	*****		1
21	kressner	p	1999	192	186	colorectal	IHC	survival	local preop	53% DO-7		*****	
160	kressner	p	1996	260	260	colorectal	IHC	survival	post surg. adj.	54% DO-7	0.01	*****	
159	kressner	p	1996	294	294	colorectal	IHC	FFS	post surg. adj.	55% DO-7	0.01	*****	
161	lanza	p	1996	141	204	colorectal	IHC	survival	post surg. adj.	61% DO-7	0.05	*****	
7	lashner	p	2003	75	75	colorectal	IHC	survival	post surg. adj.	51% DO-7	0.05	*****	
162	lazaris	p	1995	60	60	colorectal	IHC	survival	post surg. adj.	47% Pab-1801	0.1	*****	
164	leahy	p	1996	66	66	colorectal	mut	survival	post surg. adj.	41% *****	*****		5

id	study	pa	year	size with	size	site	method	endpoint	context	% with		criterion	from exon
				data	overall					p53	antibody		
163	leahy	p	1996	70	66	colorectal	IHC	survival	post surg. adj.	47%	DO-7	0.1	*****
244	lenz	p		36	36	colorectal	mut	survival	advanced / mets.	72%	*****	*****	4
79	lenz	p	1998	45	45	colon	IHC	survival	post surg. adj.	60%	DO-7	0.1	*****
75	lenz	p	1998	45	45	colon	IHC	FFS	post surg. adj.	60%	DO-7	0.1	*****
166	liang	p	1999	166	166	rectum	mut	FFS	post surg. adj.	54%	*****	*****	2
165	liang	p	1999	0	166	rectum	IHC	FFS	post surg. adj.	50%	DO-1	0.1	*****
168	luna-perez	p	1998	26	26	rectum	IHC	response	local preop	54%	Pab-1801	0.1	*****
31	maeda	p	1997	101	101	colorectal	IHC	FFS	post surg. adj.	39%	DO-7	0.01	*****
54	manne	p	1997	131	131	colorectal	IHC	survival	post surg. adj.	45%	53-12	0.1	*****
169	manne	p	1998	504	504	colorectal	IHC	survival	post surg. adj.	52%	53-12	0.1	*****
170	morrin	p	1994	52	52	colorectal	IHC	survival	post surg. adj.	62%	DO-7	0.99	*****
171	mulder	p	1995	109	109	colorectal	IHC	survival	post surg. adj.	39%	DO-7	0.3	*****
172	nasierowski	p	2001	27	204	rectum	IHC	response	local preop	48%	DO-7	0.1	*****
173	nathanson	p	1994	84	84	colorectal	IHC	survival	post surg. adj.	62%	Pab-1801	0.01	*****
174	nehls	p	1999	100	100	rectum	IHC	FFS	local preop	55%	DO-1	0.05	*****
58	nitti	p	1998	69	69	colorectal	IHC	survival	advanced / mets.	64%	DO-1	0.1	*****
175	offner	p	1995	109	109	colorectal	IHC	survival	post surg. adj.	55%	CM-1	0.01	*****
177	ogiwara	p	1994	39	39	rectum	IHC	survival	post surg. adj.	36%	DO-7	0.99	*****
176	ogiwara	p	1994	39	39	rectum	IHC	local control	post surg. adj.	36%	DO-7	0.99	*****
178	okonkwo	p	2001	25	25	rectum	IHC	response	local preop	40%	DO-7	0.1	*****
180	okubo	p	2001	110	110	colorectal	mut	survival	post surg. adj.	37%	*****	*****	2
179	okubo	p	2001	110	110	colorectal	IHC	survival	post surg. adj.	44%	DO-7	0.2	*****
182	paradiso	p	2002	75	80	colorectal	IHC	survival	advanced / mets.	43%	Pab-1801	0.05	*****
181	paradiso	p	2002	75	80	colorectal	IHC	response	advanced / mets.	43%	Pab-1801	0.05	*****
23	paradiso	p	2000	108	108	colorectal	IHC	response	advanced / mets.	37%	Pab-1801	0.05	*****
183	pereira	p	1997	80	80	colorectal	IHC	survival	post surg. adj.	30%	DO-7	0.1	*****
184	pocard	c	1998	21	21	colorectal	IHC	FFS	advanced / mets.	62%	DO-7	0.05	*****
186	poller	p	1997	250	250	colorectal	IHC	survival	post surg. adj.	61%	DO-1	0.01	*****
185	poller	p	1997	250	250	colorectal	IHC	local control	post surg. adj.	61%	DO-1	0.01	*****
187	pricolo	p	1996	70	70	colon	mut	survival	post surg. adj.	61%	*****	*****	5
62	pricolo	p	1997	141	141	colon	mut	survival	post surg. adj.	61%	*****	*****	5
190	qiu	p	2000	72	72	rectum	IHC	survival	local preop	69%	DO-7	*****	*****

id	study	pa	year	size with data	size overall	site	method	endpoint	context	% with abnormal			from exon
										p53	antibody	criterion	
189	qiu	p	2000	72	72	rectum	IHC	FFS	local preop	69%	DO-7		*****
188	qiu	p	2000	72	72	rectum	IHC	response	local preop	69%	DO-7		*****
	9	rau	p	2003	51	66	rectum	mut	survival	16%	*****	*****	5
	8	rau	p	2003	65	66	rectum	IHC	survival	43%	DO-7		*****
	57	rebischung	p	2002	86	86	rectum	mut	survival	51%	*****	*****	2
	191	rebischung	p	2002	86	86	rectum	mut	response	51%	*****	*****	2
	193	remvikos	p	1992	78	78	colorectal	IHC	survival	67%	multiple	0.99	*****
	192	remvikos	p	1992	78	78	colorectal	IHC	FFS	67%	multiple	0.99	*****
	35	rew	p	1996	82	82	colorectal	IHC	survival	50%	Pab-1801	0.99	*****
	197	rodel	p	2002	39	44	rectum	IHC	FFS	45%	DO-7	0.1	*****
	198	rodel	p	2002	54	54	rectum	IHC	FFS	46%	DO-7	0.1	*****
	196	rodel	p	2002	54	54	rectum	IHC	local control	46%	DO-7	0.1	*****
	195	rodel	p	2002	42	44	rectum	IHC	response	45%	DO-7	0.1	*****
	194	rodel	p	2002	54	54	rectum	IHC	metastases	46%	DO-7	0.1	*****
	200	rosty	p	2001	49	56	colorectal	mut	survival	63%	*****	*****	4
	199	rosty	p	2001	56	56	colorectal	mut	response	63%	*****	*****	4
	52	russo	p	2002	160	160	colorectal	mut	survival	43%	*****	*****	5
	45	russo	p	2002	160	160	colorectal	mut	FFS	43%	*****	*****	5
	201	russo	p	1998	35	35	colorectal	mut	survival	43%	*****	*****	5
	202	sakakura	p	1998	28	28	rectum	mut	response	50%	*****	*****	4
	25	samowitz	p	2002	1462	1464	colon	mut	survival	45%	*****	*****	5
	2	saw	p	2003	60	78	rectum	mut	local control	55%	*****	*****	5
	5	saw	p	2003	60	78	rectum	mut	response	55%	*****	*****	5
	204	saw	p	2002	60	60	colorectal	mut	survival	58%	*****	*****	5
	3	saw	p	2003	60	78	rectum	IHC	survival	55%	DO-7	0.01	*****
	1	saw	p	2003	60	78	rectum	IHC	local control	55%	DO-7	0.01	*****
	4	saw	p	2003	60	78	rectum	IHC	response	55%	DO-7	0.01	*****
	203	saw	p	2002	63	63	colorectal	IHC	survival	44%	DO-7	0.05	*****
	40	schelwies	p	2002	76	59	colorectal	mut	survival	47%	*****	*****	5
	205	schelwies	p	2002	57	57	colorectal	mut	survival	32%	*****	*****	5
	206	schwandnep	p	2002	160	160	rectum	IHC	survival	39%	DO-1	0.1	*****
	208	schwandnep	p	2000	160	160	rectum	IHC	survival	39%	DO-1	0.1	*****

id	study	pa	year	size with	size	site	method	endpoint	context	% with			from exon
				data	overall					p53	antibody	criterion	
73	schwandnep	p	2002	160	160	rectum	IHC	FFS	post surg. adj.	39%	DO-1	0.1	*****
207	schwandnep	p	2000	160	160	rectum	IHC	FFS	post surg. adj.	39%	DO-1	0.1	*****
210	scott	p	1991	52	52	colorectal	IHC	survival	post surg. adj.	42%	Pab421	0.7	*****
209	scott	p	1998	22	22	rectum	IHC	response	local preop	59%	DO-7	0.33	*****
213	smith	p	1996	100	100	colorectal	mut	survival	post surg. adj.	51%	*****	*****	
211	smith	p	1996	100	100	colorectal	IHC	survival	post surg. adj.	62%	Pab-1801	0.01	*****
212	smith	p	1996	100	100	colorectal	IHC	survival	post surg. adj.	76%	Pab240	0.01	*****
246	smith	p	2003	24	24	colorectal	IHC	survival	post surg. adj.		DO-1	0.99	*****
247	smith	p	2003	24	24	colorectal	IHC	survival	post surg. adj.		DO-1	0.1	*****
18	soong	p	1997	541	541	colorectal	mut	survival	post surg. adj.	36%	*****	*****	5
19	soong	p	2000	948	948	colorectal	mut	survival	post surg. adj.	38%	*****	*****	4
14	soong	p	1997	541	541	colorectal	IHC	survival	post surg. adj.	30%	DO-7	0.05	*****
214	sory	p	1997	50	50	colorectal	IHC	metastases	post surg. adj.	40%	rsp53	0.33	*****
215	spitz	p	1997	42	42	rectum	IHC	response	local preop	55%	DO-1	0.1	*****
217	starzynska	p	1997	102	102	colorectal	IHC	survival	post surg. adj.	46%	CM-1	0.01	*****
219	starzynska	p	1992	80	107	colorectal	IHC	survival	post surg. adj.	46%	CM-1	0.01	*****
216	starzynska	p	1997	102	102	colorectal	IHC	FFS	post surg. adj.	46%	CM-1	0.01	*****
218	starzynska	p	1992	80	107	colorectal	IHC	FFS	post surg. adj.	46%	CM-1	0.01	*****
13	sturm	p	1999	40	40	colorectal	mut	survival	advanced / mets.	35%	*****	*****	8
220	sturm	p	1999	40	40	colorectal	IHC	survival	advanced / mets.	60%	DO-7	0.1	*****
221	subramani	p	1995	56	56	rectum	IHC	local control	post surg. adj.	46%	CM-1	0.01	*****
32	sun	p	1993	238	238	colorectal	IHC	survival	post surg. adj.	39%	CM-1	0.01	*****
55	sun	p	1995	238	238	colorectal	IHC	survival	post surg. adj.		CM-1	0.01	*****
222	sun	p	1997	256	256	colorectal	IHC	survival	post surg. adj.	23%	CM-1	0.05	*****
223	sun	p	1996	104	293	colorectal	IHC	survival	post surg. adj.	38%	CM-1	0.01	*****
224	suzuki	p	1994	67	67	colorectal	IHC	FFS	post surg. adj.	51%	Pab-1801	0.01	*****
225	tollenaar	p	1998	238	238	colorectal	IHC	survival	post surg. adj.	40%	DO-7	0.3	*****
243	tomoda	p	1995	144	144	colorectal	IHC	FFS	post surg. adj.	25%	CM-1	0.99	*****
56	tortola	p	1999	132	151	colorectal	mut	survival	post surg. adj.	50%	*****	*****	4
226	tullo	p	1999	40	40	colorectal	mut	FFS	advanced / mets.	45%	*****	*****	5
227	wang	a	1998	40	40	colorectal	IHC	survival	post surg. adj.	65%	other	0.99	*****
228	watanabe	p	2002	78	78	rectum	IHC	survival	local preop	38%	DO-7	0.4	*****

id	study	pa	year	size with data	size overall	site	method	endpoint	context	% with abnormal			
										p53	antibody	criterion	from exon
229	wiggenraacp		1998	123	123	rectum	IHC	survival	post surg. adj.	48% DO-7		0.1	*****
36	wiggenraacp		1998	123	123	rectum	IHC	local control	post surg. adj.	48% DO-7		0.1	*****
230	yamaguchi p		1993	203	203	colorectal	IHC	survival	post surg. adj.	60% Pab-1801		0.01	*****
232	yamaguchi p		1992	100	100	colorectal	IHC	survival	post surg. adj.	61% Pab-1801		0.99	*****
231	yamaguchi p		1992	76	76	colorectal	IHC	FFS	post surg. adj.	55% Pab-1801		0.99	*****
235	yamamura p		1999	144	144	colorectal	IHC	survival	post surg. adj.	50% CM-1		0.1	*****
233	yamamura p		1999	144	144	colorectal	IHC	FFS	post surg. adj.	50% CM-1		0.1	*****
234	yamamura p		1999	142	142	colorectal	IHC	FFS	post surg. adj.	50% CM-1		0.2	*****
236	yang	p	2001	35	35	colorectal	mut	survival	advanced / mets.	66% *****	*****		5
238	yoshikawa p		2002	63	63	rectum	IHC	local control	post surg. adj.	49% DO-7		0.01	*****
237	yoshikawa p		2002	63	63	rectum	IHC	metastases	post surg. adj.	51% DO-7		0.01	*****
72	zeng	p	1994	107	107	colorectal	IHC	survival	post surg. adj.	47% Pab-1801		0.01	*****
63	zeng	p	1994	107	107	colorectal	IHC	FFS	post surg. adj.	47% Pab-1801		0.01	*****
239	zeng	p	1994	107	107	colorectal	IHC	local control	post surg. adj.	47% Pab-1801		0.01	*****
240	zhang	p	1999	235	245	colorectal	IHC	survival	post surg. adj.	62% multiple		0.01	*****
245	zirbes	p	2000	294	294	colorectal	IHC	survival	post surg. adj.	68% other		0.5	*****



study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
adell	p	1999	*****	*****	6	5.25	retro. cohort	0%	linkoping	sweden
adell	p	1999	*****	*****	8	5.25	retro. cohort	0%	linkoping	sweden
adell	p	1999	*****	*****	8	5.25	retro. cohort	0%	linkoping	sweden
adrover	p	1999	*****	*****	5	5	retro. cohort	13%	madrid	spain
ahnen	p	1998	*****	*****	14	8	retro sel.	47%	swog	usa
allegra	p	2003	*****	*****	5	5	retro sel.	62%	nsabp	usa
allegra	p	2002	*****	*****	6	5	retro sel.	68%	ncctg	usa
allegra	p	2003	*****	*****	5	5	retro sel.	62%	nsabp	usa
aoki	p	2002	8	4	8		retro sel.	.	tokyo	japan
auvinenen	p	1994	*****	*****	7		retro. cohort	.	tampere	finland
backus	p	2001	*****	*****	5		prosp.cohort	100%	amsterdam	netherlands
backus	p	2001	*****	*****			prosp.cohort	100%	amsterdam	netherlands
baretton	p	1996	*****	*****	5		retro. unsel.	.	munich	germany
bartik	p	1997	*****	*****	8		retro. cohort	.	linkoping	sweden
bell	p	1993	*****	*****	5	2.8	prosp.cohort	.	leeds	uk
belluco	p	1996	*****	*****	3	1.85	prosp.cohort	100%	mski	usa
belluco	p	1996	*****	*****		1.85	prosp.cohort	100%	mski	usa
benhattar	p	1996	8	4	5		prosp.cohort	100%	lausanne	switzerland
berglund	p	2002	*****	*****			retro. cohort	100%	upsala	sweden
bhatavdekar	p	1997	*****	*****	2	2.5	retro sel.	.	ahmedabad	india
bleeker	p	2001	8	4	5	4	prosp.cohort	100%	groningen	netherlands
borreson-d	p	1998	8	4	8	4.7	prosp.cohort	0%	oslo	norway
bosari	p	1995	8	4	7		retro. cohort	.	burlington	usa
bosari	p	1994	*****	*****	7		retro. cohort	.	burlington	usa
bouzoureni	p	2000	8	4		5.5	retro. cohort	.	lausanne	switzerland
bouzoureni	p	2000	*****	*****	6	5.5	retro. cohort	.	lausanne	switzerland
brett	p	1996	*****	*****			prosp.cohort	100%	liverpool	uk
buglioni	p	2001	*****	*****	5		retro. cohort	38%	rome	italy
buglioni	p	1999	*****	*****	5		retro. cohort	.	rome	italy
buglioni	p	2001	*****	*****	5		retro. cohort	38%	rome	italy
buglioni	p	1999	*****	*****	5		retro. cohort	.	rome	italy
bukholm	p	2000	*****	*****		4	retro. cohort	.	nordbyhagen	norway

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
bukholm	p	2000	*****	*****			4 retro. cohort	.	nordbyhagen	norway
caldes	p	1998		9	5	3	4 prosp.cohort	.	madrid	spain
caldes	p	1998	*****	*****		3	4 prosp.cohort	.	madrid	spain
cascinu	p	2000	*****	*****			retro. cohort	100%	parma	italy
cascinu	p	2002	*****	*****		4	retro. cohort	100%	parma	italy
chen	p	1997	*****	*****			2 retro. cohort	14%	minnesota	usa
chen	p	1997	*****	*****			2 retro. cohort	.	minnesota	usa
chen	p	1997	*****	*****			2 retro. cohort	.	minnesota	usa
clarke	p	1999	*****	*****		5	5 retro. cohort	.	dublin	ireland
costa	p	1997	*****	*****		4	prosp.cohort	0%	milan	italy
desai	p	1996	*****	*****			retro. cohort	22%	st louis	usa
desai	p	1996	*****	*****			retro. cohort	22%	st louis	usa
diez	p	1997	*****	*****			1.8 retro. cohort	0%	madrid	spain
diez	p	1997	*****	*****			1.8 retro. cohort	81%	madrid	spain
diez	p		*****	*****		5	2.5 retro. cohort	.	madrid	spain
diez	p		*****	*****		5	2.5 retro. cohort	.	madrid	spain
diez	p	2000	*****	*****			2.3 retro. cohort	.	madrid	spain
diez	p	1995	*****	*****		5	retro. cohort	.	madrid	spain
diez	p		*****	*****		5	2.5 retro. cohort	.	madrid	spain
dominguez a		1994	*****	*****			retro. cohort	.	asturias	spain
edler	p	2000	*****	*****			8 retro. cohort	0%	stockholm	sweden
edler	p	2000	*****	*****			8 retro. cohort	0%	stockholm	sweden
elsaleh	p	2000		8	4		retro. cohort	100%	nedlands	australia
elsaleh	p	2000			1		retro. cohort	100%	nedlands	australia
elsaleh	p	1999		8	4	5	4.8 retro. cohort	29%	nedlands	australia
elsaleh	p	2000	*****	*****			retro. cohort	100%	nedlands	australia
elsaleh	p	1999	*****	*****		5	4.8 retro. cohort	29%	nedlands	australia
esposito	p	2001	*****	*****			prosp.cohort	100%	padova	italy
etienne	p	2002		9	6	4	prosp.cohort	100%	nice	france
fante	p	1996	*****	*****		5	retro. cohort	.	modena	italy
finkelstein	p	1996		8	4	5	7 retro. cohort	100%	pittsburgh	usa
flamini	p	1996	*****	*****		4	3 retro. cohort	.	rome	italy

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
fraczadi	p	2003	*****	*****	2		1.5 retro. cohort	100%	budapest	hungary
fu	p	1998	*****	*****			4.5 retro. cohort	0%	tokyo	japan
fu	p	1998	*****	*****			4.5 retro. cohort	0%	tokyo	japan
gallego	p	2000	*****	*****	5		5 retro. cohort	0%	madrid	spain
gallego	p	2000	*****	*****	5		5 retro. cohort	0%	madrid	spain
garrity	p	2004	*****	*****	5		8 retro. sel.	0%	minnesota	usa
garrity	p	2004	*****	*****	5		8 retro. sel.	0%	minnesota	usa
gervaz	p	2001	8	4			5.5 retro. cohort	0%	lausanne	switzerland
gervaz	p	2001	*****	*****	6		5.5 retro. cohort	0%	lausanne	switzerland
gervaz	p	2002	*****	*****	6		5.5 retro. cohort	0%	lausanne	switzerland
giatomanc	p	1999	*****	*****	3		2.3 retro. cohort	48%	athens	greece
giatomanc	p	2001	*****	*****			2.6 retro. cohort	40%	athens	greece
giatomanc	p	1999	*****	*****			2.3 retro. cohort	48%	athens	greece
giatomanc	p	2001	*****	*****			2.6 retro. cohort	.	athens	greece
giatomanc	p	2001	*****	*****			2.6 retro. cohort	40%	athens	greece
giatomanc	p	2001	*****	*****			2.6 retro. cohort	.	athens	greece
goh	p	1999	9	6			3.5 retro. cohort	.	singapore	singapore
goh	p	1999	9	6			3.5 retro. cohort	.	singapore	singapore
goh	p	1999	9	6			3.5 retro. cohort	.	singapore	singapore
gonzalez-a	p	2004			5		retro. cohort	.	madrid	spain
grewal	p	1995	*****	*****	7		3.2 retro. cohort	0%	new york	usa
grewal	p	1995	*****	*****			3.2 retro. cohort	0%	new york	usa
gunther	p	2002	*****	*****			7 retro sel.	0%	erlangen	germany
hallak	p	1998	*****	*****			retro. cohort	.	ulm	germany
hamelin	p	1994	8	4	6		4 retro. cohort	0%	paris	france
hardinghan	p	1998	8	4	5		retro. cohort	.	woodville	australia
haseba	p	2003	9	5	4		2.75 retro. cohort	44%	nagasaki	japan
hayashi	p	1995	8	4			retro. cohort	.	tokyo	japan
heisterkam	p	1999	*****	*****	5		retro. cohort	.	rotterdam	netherlands
hirano	p	2000	*****	*****			4.2 retro. cohort	.	kanazawa	japan
hirvikoski	p	1999	8	5			2.8 retro sel.	.	kuopio	finland
hirvikoski	p	1999	*****	*****			2.8 retro sel.	.	kuopio	finland

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
hirvikoski	p	1999	*****	*****			2.8 retro sel.	.	kuopio	finland
ichikawa	p	1996		9	5		retro sel.	100%	kyoto	japan
ilyas	p	1998	*****	*****			6 retro sel.	.	london	uk
iniesta	p	1998		9	5	4	retro. cohort	.	madrid	spain
jansson	p	2001		9	5		10 retro. cohort	.	linkoping	sweden
jingwei	a	1998	*****	*****			retro sel.	.	wuhan	china
kahlenberg	p	2000		9	5	5	prosp.cohort	.	san antonic	usa
kahlenberg	p	2000		9	5	5	prosp.cohort	.	san antonic	usa
kandolier	p	2002		10	9	4	prosp.cohort	23%	vienna	austria
kandolier	p	2002		10	9		prosp.cohort	23%	vienna	austria
kandolier	p	2002		10	9		prosp.cohort	23%	vienna	austria
kandolier	p	2002		10	9		prosp.cohort	23%	vienna	austria
kang	p	1997	*****	*****		5	5 retro. cohort	.	osaka	japan
kang	p	1997	*****	*****		5	5 retro. cohort	.	osaka	japan
kapiteijn	p	2001	*****	*****		4	retro sel.	.	leiden	netherlands
kapiteijn	p	2001	*****	*****		4	retro sel.	.	leiden	netherlands
khan	p	2001		9	6		1 prosp.cohort	100%	london	uk
kim	p	2001	*****	*****			prosp.cohort	100%	seoul	korea
kim	p	1995	*****	*****		5	retro. cohort	.	seoul	korea
klump	p	2003	*****	*****		8	3.9 retro. cohort	0%	dusseldorf	germany
klump	p	2003	*****	*****		8	3.9 retro. cohort	0%	dusseldorf	germany
klump	p	2003	*****	*****		8	3.9 retro. cohort	0%	dusseldorf	germany
kotera	p	1997	*****	*****		8	retro. cohort	.	hyogo	japan
kotera	p	1997	*****	*****		8	retro. cohort	.	hyogo	japan
kressner	p	1999		11	11	8	prosp.cohort	0%	uppsala	sweden
kressner	p	1999	*****	*****		8	prosp.cohort	0%	uppsala	sweden
kressner	p	1996	*****	*****		8	retro. cohort	0%	uppsala	sweden
kressner	p	1996	*****	*****			retro. cohort	0%	uppsala	sweden
lanza	p	1996	*****	*****		3	2.5 retro. cohort	24%	ferrara	italy
lashner	p	2003	*****	*****		10	retro. cohort	.	cleveland	usa
lazaris	p	1995	*****	*****			retro. cohort	.	athens	greece
leahy	p	1996		8	4	5	retro. cohort	0%	dublin	ireland

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
leahy	p	1996	*****	*****	5	10	retro. cohort	0%	dublin	ireland
lenz	p			11	8	2	prosp.cohort	100%	los angeles	usa
lenz	p	1998	*****	*****	1		retro. cohort	0%	los angeles	usa
lenz	p	1998	*****	*****			retro. cohort	0%	los angeles	usa
liang	p	1999		11	10	7	retro. cohort	100%	taipei	taiwan
liang	p	1999	*****	*****			retro. cohort	100%	taipei	taiwan
luna-perez	p	1998	*****	*****			retro. cohort	100%	mexico city	mexico
maeda	p	1997	*****	*****	5	5	retro. cohort	.	osaka	japan
manne	p	1997	*****	*****	10		retro sel.	.	birmingham	usa
manne	p	1998	*****	*****	10	4	retro sel.	.	birmingham	usa
morrin	p	1994	*****	*****	5	5	retro. cohort	.	limerick	ireland
mulder	p	1995	*****	*****	10		retro. cohort	.	leiden	netherlands
nasierowski	p	2001	*****	*****			retro. cohort	0%	warsaw	poland
nathanson	p	1994	*****	*****	7		retro. cohort	0%	detroit	usa
nehls	p	1999	*****	*****	10	6	retro. cohort	.	dusseldorf	germany
nitti	p	1998	*****	*****	4	3	prosp.cohort	26%	padova	italy
offner	p	1995	*****	*****	10	7.9	retro. cohort	0%	munster	germany
ogiwara	p	1994	*****	*****			retro. cohort	.	hamamatsi	japan
ogiwara	p	1994	*****	*****			retro. cohort	.	hamamatsi	japan
okonkwo	p	2001	*****	*****			retro. cohort	100%	chicago	usa
okubo	p	2001		11	10	5	prosp.cohort	.	tokyo	japan
okubo	p	2001	*****	*****	5		prosp.cohort	.	tokyo	japan
paradiso	p	2002	*****	*****			retro. cohort	94%	neuquen	argentina
paradiso	p	2002	*****	*****			retro. cohort	94%	neuquen	argentina
paradiso	p	2000	*****	*****			retro. cohort	100%	neuquen	argentina
pereira	p	1997	*****	*****		5	retro. cohort	0%	lisbon	portugal
pocard	c	1998	*****	*****			retro. cohort	.	paris	france
poller	p	1997	*****	*****	5	5	retro. cohort	.	gloucester	uk
poller	p	1997	*****	*****		5	retro. cohort	.	gloucester	uk
pricolo	p	1996		8	4	7	retro. cohort	100%	providence	usa
pricolo	p	1997		8	4	7	retro. cohort	50%	providence	usa
qiu	p	2000	*****	*****			retro. cohort	71%	minnesota	usa

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
qiu	p	2000	*****	*****			retro. cohort	71%	minnesota	usa
qiu	p	2000	*****	*****			retro. cohort	71%	minnesota	usa
rau	p	2003	8	4	3		prosp.cohort	100%	berlin	germany
rau	p	2003	*****	*****	3		prosp.cohort	100%	berlin	germany
rebischung	p	2002	11	10	5	4	prosp.cohort	0%	lyon	france
rebischung	p	2002	11	10		4	prosp.cohort	0%	lyon	france
remvikos	p	1992	*****	*****	5		retro. cohort	.	paris	france
remvikos	p	1992	*****	*****	5		retro. cohort	.	paris	france
rew	p	1996	*****	*****	4	2.5	prosp.cohort	.	leicester	uk
rodel	p	2002	*****	*****			retro. cohort	100%	erlangen	germany
rodel	p	2002	*****	*****		2.3	retro. cohort	100%	erlangen	germany
rodel	p	2002	*****	*****		2.3	retro. cohort	100%	erlangen	germany
rodel	p	2002	*****	*****			retro. cohort	100%	erlangen	germany
rodel	p	2002	*****	*****		2.3	retro. cohort	100%	erlangen	germany
rosty	p	2001	9	6	3		prosp.cohort	100%	nice	france
rosty	p	2001	9	6			prosp.cohort	100%	nice	france
russo	p	2002	8	4	5	6	prosp.cohort	6%	palermo	italy
russo	p	2002	8	4	5	6	prosp.cohort	6%	palermo	italy
russo	p	1998	8	4			prosp.cohort	.	palermo	italy
sakakura	p	1998	8	5			prosp.cohort	100%	kyoto	japan
samowitz	p	2002	8	4		5	retro. cohort	.	utah	usa
saw	p	2003	8	4		3.9	retro. cohort	45%	sydney	australia
saw	p	2003	8	4		3.9	retro. cohort	45%	sydney	australia
saw	p	2002	8	4			retro. cohort	.	sydney	australia
saw	p	2003	*****	*****		3.9	retro. cohort	45%	sydney	australia
saw	p	2003	*****	*****		3.9	retro. cohort	45%	sydney	australia
saw	p	2003	*****	*****		3.9	retro. cohort	45%	sydney	australia
saw	p	2002	*****	*****			retro. cohort	.	sydney	australia
schelwies	p	2002	8	4	8	5	retro. cohort	5%	berlin	germany
schelwies	p	2002	8	4	8	5	retro. cohort	5%	berlin	germany
schwandne	p	2002	*****	*****		3.2	retro. cohort	57%	lubeck	germany
schwandne	p	2000	*****	*****	6	3.2	retro. cohort	57%	lubeck	germany

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
schwandne	p	2002	*****	*****			3.2 retro. cohort	57%	lubeck	germany
schwandne	p	2000	*****	*****			3.2 retro. cohort	57%	lubeck	germany
scott	p	1991	*****	*****	3		prosp.cohort	.	leeds	uk
scott	p	1998	*****	*****			retro. cohort	100%	stoke	uk
smith	p	1996			1	4	2 prosp.cohort	0%	singapore	singapore
smith	p	1996	*****	*****		4	2 prosp.cohort	0%	singapore	singapore
smith	p	1996	*****	*****		4	2 prosp.cohort	.	singapore	singapore
smith	p	2003	*****	*****		5	4 retro. cohort	.	new york	usa
smith	p	2003	*****	*****		5	4 retro. cohort	.	new york	usa
soong	p	1997	8		4	7	3 retro. cohort	5%	nedlands	australia
soong	p	2000	1		-2		retro. cohort	17%	nedlands	australia
soong	p	1997	*****	*****		7	3 retro. cohort	5%	nedlands	australia
sory	p	1997	*****	*****			retro. cohort	.	kanazawa	japan
spitz	p	1997	*****	*****			retro. cohort	100%	houston	usa
starzynska	p	1997	*****	*****		5	5.5 retro. cohort	3%	mancheste	uk
starzynska	p	1992	*****	*****			1 retro. cohort	.	mancheste	uk
starzynska	p	1997	*****	*****		5	5.5 retro. cohort	3%	mancheste	uk
starzynska	p	1992	*****	*****			1 retro. cohort	.	mancheste	uk
sturm	p	1999			-7	6	retro. cohort	73%	berlin	germany
sturm	p	1999	*****	*****		6	retro. cohort	73%	berlin	germany
subramani	p	1995	*****	*****			2.3 retro. cohort	.	hobart	australia
sun	p	1993	*****	*****		8	retro. cohort	.	linkoping	sweden
sun	p	1995	*****	*****		8	retro. cohort	.	linkoping	sweden
sun	p	1997	*****	*****		10	10 retro. cohort	.	linkoping	sweden
sun	p	1996	*****	*****		8	retro. cohort	.	linkoping	sweden
suzuki	p	1994	*****	*****		3	2 prosp.cohort	.	edobashi	japan
tollenaar	p	1998	*****	*****		7	2 retro. cohort	0%	leiden	netherlands
tomoda	p	1995	*****	*****		2	1.5 retro. cohort	0%	fukuoka	japan
tortola	p	1999	9		6	5	4.3 retro. cohort	21%	barcelona	spain
tullo	p	1999	9		5		2.3 prosp.cohort	.	bari	italy
wang	a	1998	*****	*****			retro. cohort	.		china
watanabe	p	2002	*****	*****		5	retro. cohort	0%	tokyo	japan

study	pa	year	to exon	exons	time- point	median fup	design	Chemo	city region	country
wiggenraac	p	1998	*****	*****	6	3.3	retro. cohort	0%	leiden	netherlands
wiggenraac	p	1998	*****	*****	6	3.3	retro. cohort	0%	leiden	netherlands
yamaguchi	p	1993	*****	*****	10		retro. cohort	.	kanazawa	japan
yamaguchi	p	1992	*****	*****	4		retro. cohort	.	kanazawa	japan
yamaguchi	p	1992	*****	*****			retro. cohort	.	kanazawa	japan
yamamura	p	1999	*****	*****	5		retro. cohort	100%	kawasaki	japan
yamamura	p	1999	*****	*****	5		retro. cohort	100%	kawasaki	japan
yamamura	p	1999	*****	*****			retro. cohort	.	kawasaki	japan
yang	p	2001	9	5	5		prosp.cohort	0%	goteborg	sweden
yoshikawa	p	2002	*****	*****			retro. cohort	.	tsu	japan
yoshikawa	p	2002	*****	*****			retro. cohort	.	tsu	japan
zeng	p	1994	*****	*****	6	5	retro. cohort	19%	new york	usa
zeng	p	1994	*****	*****	6	5	retro. cohort	19%	new york	usa
zeng	p	1994	*****	*****	6	5	retro. cohort	19%	new york	usa
zhang	p	1999	*****	*****	8		retro. cohort	.	linkoping	sweden
zirbes	p	2000	*****	*****	10	4.7	retro. cohort	.	cologne	germany